[The treatment of migraine].
Titus
F
F
Unidad de Cefaleas, Hospital General Universitario Vall d'Hebron, Barcelona, España.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000639:Amitriptyline / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004087:Dihydroergotamine / Q000627:therapeutic use; D004878:Ergotamine / Q000627:therapeutic use; D005444:Flunarizine / Q000627:therapeutic use; D006801:Humans; D008784:Methysergide / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy* / Q000517:prevention & control; D009529:Nicardipine / Q000627:therapeutic use; D009553:Nimodipine / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000627:therapeutic use; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D018170:Sumatriptan / Q000627:therapeutic use; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D014662:Vasoconstrictor Agents; D000639:Amitriptyline; D004087:Dihydroergotamine; D009553:Nimodipine; D018170:Sumatriptan; D009529:Nicardipine; D004878:Ergotamine; D005444:Flunarizine; D008784:Methysergide
Tratamiento de la migraña.